Pilocytic astrocytoma (PA) is the most common primary brain tumor in children; various signaling pathways have been implicated in its biology. The Notch signaling pathway has been found to play a role in the development, stem cell biology, and pathogenesis of several cancers, but its role in PA has not been investigated. We studied alterations in Notch signaling components in tumor tissue from 18 patients with PA and 4 with other low-grade astrocytomas to identify much needed therapeutic targets. We found that Notch pathway members were overexpressed at the mRNA (NOTCH1, NOTCH2, HEY1, HEY2) and protein (HES1) levels in PAs at various anatomic sites compared with non-neoplastic brain samples. These changes were not associated with specific BRAF alterations. Inhibiting the Notch pathway in the pediatric low-grade astrocytoma cell lines Res186 and Res259 using either RNA interference or a Fsecretase inhibitor resulted in variable, but significant, reduction in cell growth and migration. This study suggests a potential role for Notch signaling in pediatric low-grade astrocytoma tumorigenesis and that Notch signaling may be a viable pathway therapeutic target.
INTRODUCTION
Pediatric low-grade astrocytomas (PLGAs) encompass the most frequent primary brain tumors afflicting children. These tumors are characterized by slow growth and relatively circumscribed architecture, which allows for gross total resection and surgical cures in many patients. However, a subset of these tumors progresses, particularly when they are located in inaccessible surgical sites, and may then be associated with significant morbidity and even mortality across time. Given the toxicities and relatively inefficacy associated with conventional therapies (i.e. chemoradiation), novel rational targeted therapies based on our increasing knowledge of the biology of these tumors are needed.
Recent applications of high-resolution platforms have uncovered important somatic genetic drivers that are relatively specific to PLGA subtypes. For instance, duplications of the BRAF kinase domain resulting in BRAF-KIAA1549 fusions are present in most pilocytic astrocytomas (PAs), the predominant histologic subtype of PLGA (1Y5). These alterations lead to increased downstream signaling pathways that have been found to be active in PLGA, particularly mitogen-activated protein kinase (MAPK) (2) . The mammalian target of rapamycin (mTOR) pathway is also often active in these tumors (6, 7) . Other PLGA subtypes have different alterations. For example, MYB, MYBL1, and FGFR1 mutations or rearrangements are typical of pediatric diffuse astrocytomas (8, 9) .
The Notch signaling pathway plays important roles in the development and, when deregulated, in disease (10) . Notch activity also has critical functional roles in a variety of cancers, including those of hematopoietic origin, skin, breast, ovarian, lung, prostate, and pancreas (11Y16). Although Notch receptors and ligands function as bona fide oncoproteins in many cancers, tumor suppressor roles may also predominate in specific subtypes or contexts (14) .
Canonical Notch signaling functions through direct cell-tocell interactions. The pathway is turned on when a Notch ligand on 1 cell binds to a Notch receptor on an adjacent cell (Fig. 1) . Once bound, the Notch receptor goes through 2 proteolytic cleavages. It is first cut extracellularly by an ADAM protease and then within the membrane by F-secretase. After the second cleavage, the notch intracellular domain translocates to the nucleus, where it binds to a CBF1/Suppressor of Hairless/LAG-1 family DNA-binding protein. This binding then activates transcription of pathway targets, primarily members of the HES and HEY families, which in turn function as transcriptional repressors. These repressors affect cellular proliferation and differentiation in both embryogenesis and carcinogenesis (17) . In addition, cross talk with other oncogenic canonical pathways has also been described (10) , including in the context of astrocytic tumors (18) .
Recent studies have also started to uncover a role for Notch signaling in glioma biology. Specifically, Notch signaling seems to play a role in cancer stem cell maintenance in gliomas (19Y21) and may also regulate other key glioma cell properties such as migration and invasion (22, 23) . Interestingly, Notch3 activation induces gliomas in murine eye and optic nerve (24) , a frequent site for PLGA development. Moreover, in a prior gene expression study, NOTCH2 was found to be upregulated in a subset of PAs localized to the hypothalamochiasmatic region (25) . Therefore, we hypothesized that Notch signaling may play a role in the biology of PLGA and PA, in addition to other more extensively studied signaling pathways, and may be a therapeutic target.
MATERIALS AND METHODS

Primary Tumor Samples and Cell Lines
Twenty-two primary PLGAs and pooled non-neoplastic brain samples were used to quantitate gene expression. Clinicopathologic and BRAF molecular features of these tumors have been published (26) ; demographic and molecular features are summarized in the Table. A previously characterized tissue microarray containing 61 PAs and 4 non-neoplastic brain controls was also used for immunohistochemical analysis (27) . Pediatric low-grade astrocytoma cell lines Res186 (PA derived) and Res259 (diffuse astrocytoma derived) have been previously described (28) and were kindly provided by Dr Chris Jones (Institute of Cancer Research, Sutton, UK). They were maintained in Dulbecco modified Eagle medium/ F12 Ham medium (DMEM/F12), containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin in a humidified 37-C incubator with 5% CO 2 . This study was performed following institutional review guidelines at Johns Hopkins University.
Real-time Polymerase Chain Reaction
Primers for each mRNA gene target are listed in the Table, Supplemental Digital Content 1, http://links.lww.com/ NEN/A692. Total mRNA was extracted from the tissue samples and cell lines, converted to cDNA, and normalized to 5 ng/KL with 1 KL of cDNA used per reaction. The amplification protocol was as follows: denaturation at 95-C for 8 minutes, followed by 35 amplification cycles at 95-C for 10 seconds, 58.1-C for 30 seconds, and 65-C for 30 seconds. Melt curve analysis verified the absence of nonspecific polymerase chain reaction (PCR) products. The relative expression of each gene was compared with A-ACTIN for the primary samples and with HPRT1 for the cell lines.
Immunohistochemistry
Deparaffinized tissue microarray sections were stained with a HES1 antibody. Briefly, antigen retrieval was performed with citrate buffer at pH 6.0 at 95-C to 100-C. Slides were incubated with an anti-HES1 antibody (goat polyclonal, 1:100 dilution; Santa Cruz Biotechnology, Dallas, TX) for 1 hour, followed by incubation with anti-goat IgG for 1 hour. 3,3 ¶-Diaminobenzidine was used as the chromogen. A neuropathologist (Fausto J. Rodriguez) scored the stained arrays using a 4-tiered scale based on the percentage of tumor cell nuclei showing immunoreactivity as follows: 0, negative/ rare positive cells; 1, 1% to 10% positive cells; 2, 10% to 50% positive cells; and 3, more than 50% positive cells. At least 2 intact cores were required for a case to be scored.
Gene Expression Microarray Analysis
Affymetrix HG-U133 Plus 2.0 gene chip mRNA expression data from profiled PA samples and non-neoplastic brain controls were analyzed as previously described (29) . In brief, 64 PAs and 20 non-neoplastic brain samples from various anatomic regions were obtained from 3 data sets: a JHH profiled data set and 2 publically available downloadable files (GSE37307 and GSE5675). Frozen robust multiarray analysis was applied for Raw gene expression data preprocessing and normalization. To correct for multiple comparisons, the Benajmini-Hochberg method was used; a false discovery rate less than 0.001 was considered significant. The Notch pathway components and targets were organized into a heat map using the Pearson distance, average clustering method.
Drug Treatment and Plasmids
For knockdown experiments, lentiviruses, prepared in PLKO.1, encoding small hairpin RNAs (shRNAs) against CBF1 (sequence 1: GCT GGA ATA CAA GTT GAA CAA; sequence 3: GCA CAG ATA AGG CAG AGT ATA) were used, as previously described (30); they were purchased from Thermo Fisher Scientific (Waltham, MA). Infected cells were selected using 5 Kg/mL puromycin. For pharmacologic inhibition, cells were treated with the F-secretase inhibitor (GSI) MRK003, a generous donation from Merck (Whitehouse Station, NJ). During GSI treatment, the cells were incubated in DMEM/F12 containing 2% FBS.
Cellular Growth Assays
The cell titer 96 Aqueous One solution cell proliferation assay kit (Promega, Madison, WI) was used to examine cell growth using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS). Viable cells were counted and plated at a density of 1,500 cells per well in triplicate using DMEM/F12 with 2% FBS. Twenty microliters of MTS reagent was added to 100 KL medium in 96-well plates and incubated for 1 hour at 37-C in 5% CO 2 . Cells were counted at Days 0, 2, 4, and 6 for each condition: Parental, PLKO control, shScramble control, shCBF1 no. 1, and CBF1 no. 3 for molecular inhibition, DMSO control, and 2 and 5 KM of the GSI inhibitor MRK003 for pharmacologic inhibition. The 490-nm absorbance value (which is proportional to the number of viable cells in culture) was measured using an Epoch Micro-Volume Spectrophotometer Plate Reader (Biotek, Winooski, VT).
Boyden Chamber Invasion Assay
Cellular invasion was assayed by first precoating 6.5-mm-diameter Falcon cell culture inserts (8-Km pore size; Becton Dickinson, Franklin Lakes, NJ) with Matrigel diluted 1:100 with medium in 24-well plates. Cells were then added to serum-free medium in the upper chamber and allowed to invade through the Matrigel-coated pores into 10% FBSYcontaining medium in the lower chamber for 16 hours. The cells in the upper chamber were then removed, and the remaining cells on the bottom side of the culture insert were fixed in 70% EtOH and counted from 3 random highpowered fields.
Migration Assay
Cells were grown in a 6-well plate until confluence and then scratched twice with a P1000 pipette tip. The cells were rinsed in PBS 5 times, imaged at 4 separate locations, and grown overnight in DMEM/F12 with 2% FBS. Seventeen hours later, the cells were imaged again at the same 4 locations. ImageJ software (National Institutes of Health, Bethesda, MD) was then used to determine the surface area of the scratch, with the percent migration being determined by: 
Western Blot Analysis
TNE buffer, including protease inhibitors diluted to 1:100, was used to lyse the cells. Protein was transferred to nitrocellulose membranes and incubated overnight with anti-CBF1 diluted 1:1000 or antiYA-actin (Cell Signaling Technology, Danvers, MA) at 1:20,000 in 5% nonfat milk. Secondary antibodies (rabbit and/or mouse IgG) (Kirkegaard and Perry Laboratories, Inc, Gaithersburg, MD) were diluted 1:5000 in blocking solution, and the blots were developed using enhanced chemiluminescence reagent. Densitometry analysis was performed using ImageJ software with the gel analysis method described in the ImageJ documentation. 
Statistical Analysis
Experiments were performed at least 3 times unless otherwise specified. Statistics was determined using the Student t-test, with p G 0.05 considered significant. Statistical analyses were performed using Prism 6 software (GraphPad, San Diego, CA).
RESULTS
Activation of the Notch Signaling Pathway Is Frequent in PLGAs
To study the activity of the Notch signaling pathway in PLGAs, analysis of the Notch pathway was performed by qRT-PCR in 22 primary PLGAs (predominantly PA) (Table) and compared with pooled non-neoplastic brain samples. BRAF-KIAA1549 fusions were present in the majority of the tumors tested (15 of 21; 71%). The BRAF (V600E) point mutation or a clinical history of neurofibromatosis-1 was absent. Other alterations present in PLGAs lacking BRAF alterations (e.g. FGFR1 mutations, RAF1 fusions) were not tested. Components of the Notch signaling pathway and downstream targets were overexpressed in a majority of the tumors compared with pooled non-neoplastic brain samples, including those with and without BRAF alterations. (Fig. 2A) .
To study activation of the Notch signaling pathway in PAs at the protein level, the Notch target HES1 was evaluated by immunohistochemistry in 61 PAs on tissue microarrays. Ninety-five percent (58 of 61) of the PA samples exhibited some degree of nuclear HES1 staining, with 66% (40 of 61) showing moderate to strong expression (Fig. 2B) . There was no significant association between HES1 immunohistochemistry and anatomic site, the presence or absence of BRAF alterations, BRAF alteration type, or outcome (p 9 0.05).
To confirm that the Notch pathway was active in PAs, the most common subtype of PLGA, we studied global gene expression in a larger cohort of PAs profiled at Johns Hopkins combined with others obtained from publically available data sets (Affymetrix HG-U133 Plus 2.0). Using a false discovery rate less than 0.001 and excluding gene expression changes overlapping between the 3 different data set batches (to adjust for batch effect), a total of 2,682 genes were found to be differentially expressed between PAs and non-neoplastic brain tissues. This list included gene members of the Notch signaling pathway ( Fig. 3 ; Table, Supplemental Digital Content 2, http://links.lww.com/NEN/A693). Of interest, 2 separate probes showed that the known Notch target HEY2 was overexpressed more than 100-fold in tumor samples compared with nonneoplastic controls. The related family member HEY1 was overexpressed approximately 60-fold. Other genes encoding for components of the canonical Notch signaling pathway proper that were also overexpressed included the Notch ligand JAGGED1 (55-fold) and receptors NOTCH1 and NOTCH2 (12-and 6-fold, respectively). Conversely, genes encoding for other Notch ligands (e.g. Jagged2 and Delta 1, 3, and 4) were not found to be differentially expressed.
Core Binding Factor Inhibition Reduces the Growth and Migration of Res186 and Res259
To evaluate the role of Notch signaling in PLGA, lentiviruses containing short hairpins directed against CBF1, a cofactor necessary for Notch receptor binding and activation, were used to infect the PLGA-derived cell lines Res186 and Res259. We chose to inhibit core binding factor (CBF) because it is a cobinding factor for the transcriptional activation of all 4 Notch receptors, regardless of which Notch receptor is activated (i.e. global Notch signaling pathway inhibition). This approach has previously been used to inhibit canonical Notch signaling in neural stem cells (31) . Core binding factor 1 mRNA was reduced an average of 10-fold in Res186 and 5-fold in Res259 using 2 separate hairpins compared with a scrambled short hairpin control (Fig. 4A) . Core binding factor 1 knockdown resulted in a concomitant, although less pronounced, decrease in HES1 mRNA (Fig. 4B) . Protein expression of CBF1 was also significantly reduced (Fig. 4C) .
To study the effect of Notch inhibition on cellular properties, the MTS assay for cell growth was performed. The shCBF1 no. 1 and shCBF1 no. 3 inhibition of Res186 and Res259 resulted in a discernible decrease in cellular growth after just 2 days (Fig. 5A) . By 6 days, Res186 was inhibited by 44% and 63% using shCBF1 no. 1 and shCBF1 no. 3, respectively, compared with the scramble short-hairpin control; Res259 was inhibited by 58% and 64%, respectively, under the same conditions (Fig. 5B) .
Next, we studied the effect of Notch pathway inhibition on other cellular properties, including invasion and migration. In a scratch test assay, both Res186 and Res259 cell migration were inhibited compared with the shScramble control (Fig. 5C ). Combining 6 separate scratch assays, the migration of Res186 was inhibited by 23% and 18% in cells expressing shCBF1 no. 1 and shCBF1 no. 3, respectively, although the results were only statistically significant using shCBF1 no. 3. Migration of Res259 was inhibited by 34% and 36% under the same conditions (Fig. 5D) . Conversely, we did not observe a consistent effect on invasion using a Boyden chamber assay (data not shown).
Pharmacologic Inhibition of Notch Signaling Using a GSI
We sought to complement our genetic inhibition of Notch with a more clinically relevant pharmacologic approach. Treatment of Res186 with the GSI MRK003 reduced HES1 mRNA expression by 52% at 2 KM and 57% at 5 KM; in Res259, HES1 expression is inhibited by 58% at 2 KM and 61% at 5 KM (Fig. 6A) , consistent with molecular Notch pathway inhibition. The GSI inhibition trended toward decreased growth on MTS, although it was not statistically significant (Figure, Supplemental Digital Content 3, http:// links.lww.com/NEN/A694). Migration of Res186 cells was reduced by 15% and 30% in the presence of 2 and 5 KM GSI, respectively (Fig. 6B, C) . However, GSI inhibition had no discernible effect on the migration of Res259 cells.
DISCUSSION
In this study, we extend prior observations on the oncogenic role of the Notch signaling pathway to an important group of pediatric neoplasms, that is, PLGA. We sought to explore the role of Notch signaling in PLGA tumorigenesis and to determine whether Notch inhibition could potentially function as a therapeutic target.
The functional significance of Notch signaling in gliomas has been previously studied (32) . Notch signaling has been found to play a key role during brain development. In addition, Notch signaling also plays a role in the adult brain neural stem cell niche. Specifically, Notch seems to regulate adult neural stem cell maintenance (33) and prevent astrocytic differentiation in the adult subventricular zone through downstream effectors (e.g. EphB2) (34) . Dysregulation of the Notch pathway occurs through various means and, in certain contexts, can specifically facilitate gliomagenesis and lead to tumor initiation (24) . Furthermore, Notch pharmacologic blockade specifically leads to decreased glial tumorigenicity, decreased stem cell marker expression, and induction of glial differentiation (19) .
Using Notch signaling as a therapeutic target has been shown to be efficacious in a variety of research settings. Our group and others have shown that clinically relevant levels of GSI administration were able to significantly reduce tumor burden and prolong the survival of mice with glioblastoma xenografts (19, 35) . Similar results using clinically relevant GSI levels were also found in breast cancer (36) . Others have studied Notch blockade as a strategy in pediatric brain tumors. For example, a phase I clinical trial using the GSI MK-0752 in patients with pediatric brain tumors was tolerated, although it failed to show a significant response (37) . Promising results were found using the same drug on a larger cohort of adult patients with high-grade gliomas, suggesting that GSIs have the potential to be effective against gliomas (38) .
In the current study, we have shown that the Notch signaling pathway is active in most PLGA/PA tumors studied, and that it may affect cell characteristics such as growth and migration. The availability of PLGA models for functional experiments is fairly limited because in part of the phenomenon of oncogene-induced senescence that is likely secondary to BRAF activation in these tumors (27, 39) . Xenograft models of PLGA with clinically relevant attributes are particularly scant. Currently, understanding how Notch signaling is specifically activated in these tumors is unclear. In T-cell acute lymphoblastic leukemia, activating NOTCH1 mutations are frequent (40) , but similar alterations have not been identified in PLGA. Two relevant signaling pathways activated in PLGA, MAPK and mTOR, could potentially affect Notch signaling. For example, MAPK activity has been shown to regulate Notch signaling in papillary thyroid carcinoma (41) .
Most of the tumors directly tested in our study had a BRAF-KIAA1549 fusion (~71%), which is typical of PAs. Alternative alterations that also affect MAPK signaling have been described in PA (e.g. FGFR1 mutations, RAF1 fusions, and BRAF deletions or insertions) (9, 42) . In addition, some nonglial tumors with FGFR1 rearrangements have demonstrated increased Notch constitutive activity (43) . These are relatively rare in PLGA, but future studies with larger cohort numbers will elucidate whether alterations in Notch expression may vary according to specific genetic aberrations leading to increased MAPK activity.
We used 2 currently available PLGA cell lines (28) , that is, Res186 (PA derived) and Res259 (diffuse astrocytoma derived), to study the effects of Notch signaling inhibition using shRNA and pharmacologic GSI inhibition. Both approaches effectively downregulated the expression of downstream Notch targets in these cells, and shRNA-mediated inhibition of CBF1 also significantly affected cell growth. Interestingly, cell migration (but not invasion) was affected by both approaches. Although most PLGAs are circumscribed and display little tumor spread, a subset of these tumors may extend into the subarachnoid space and disseminate through the CSF, causing significant morbidity for which efficacious therapies are lacking. Inhibiting migration may, therefore, represent a complementary approach in the subset of PLGA that disseminate in this manner. Conversely, a prior study from our group using these cell lines showed that mTOR inhibition affects proliferation (6), a phenomenon studied by Kaul et al (7) in neural stem cells carrying BRAF fusions. Of interest, Notch activity may also affect the mTOR pathway in other tumors (44) . One caveat regarding pharmacologic inhibition using GSIs is that these compounds also affect other cellular dynamics, and the effects of GSI inhibition may not be completely ascribed to Notch blockade. However, GSIs have been found to inhibit Notch in preclinical studies and early-phase clinical trials of patients with solid tumors (19, 45, 46) . It is of interest that the antitumor effects were more pronounced by CBF1 knockdown, which should more specifically inhibit Notch, although effects on other cell pathways cannot be completely excluded.
Similar to the earlier mTOR study using these cell lines (6), Res186 seems to be more responsive to drug dosing than Res259. Currently, it is unclear whether this reflects a difference in drug sensitivity related to tumor type (PA vs diffuse astrocytoma) or whether it is an intrinsic property of these cell lines. As previously mentioned, it is difficult to develop PLGA lines. One caveat of the current study is that the PLGA lines used in these experiments contain genetic alterations that are relatively rare in PLGA (e.g. homozygous PTEN deletion in Res186, PDGFRA gain in Res259) (28) , which could explain some of the negative pharmacologic results. We used a drug dosage that has been found to be effective in prior glioma studies and that has been shown to inhibit Notch signaling and multiple Notch targets (19, 45) . Future studies, and greater availability of PLGA models, should provide answers to these questions and clarify the feasibility of Notch inhibition as a viable target.
In summary, this study demonstrates a high level of Notch activity in the majority of PLGAs studied; targeting this pathway could be feasible, alone or in combination, for these tumors in the future. As newer drugs with increased specificity and decreased toxicity become available, as well as more faithful in vivo models, additional studies of Notch inhibition in PLGA may be warranted.
